Creating Advancement Pathways for Our Portfolio Companies

The Investment Partner for Tomorrow’s Leaders

Fueling the next wave of innovation from Singapore to the world.

What We Do

What We Do

SG Growth Capital accelerates the growth of our portfolio companies by providing strategic capital, market expertise, and access to a global network – fuelling their expansion from Singapore to the world.

We house two investment arms: EDBI, which backs global technology leaders driving industry transformation, and SEEDS, which co-invests in early-stage startups to strengthen the local startup ecosystem.

Together, we drive the development of innovative solutions, create good jobs, and contribute to Singapore’s long-term economic resilience.

Bridging Borders

We cultivate meaningful relationships, helping Singapore startups and global companies to scale in the region and globally.

Collaborative Growth

We deepen partnerships with businesses and government agencies to create
mutual benefits.

Singapore Impact​

We amplify Singapore’s strength as an innovation hub and its position as a preferred gateway for global expansion.

Accelerating Growth Beyond Capital

At SG Growth Capital, our value lies not only in our capital but in how we partner with companies to scale strategically. From market access to leadership hiring and ecosystem partnerships, we work alongside our portfolio to drive sustainable growth. Through our value creation efforts and expansive network, we offer opportunities for:

Market & Tech Access

Ecosystem Connectivity

Talent Support

R&D Collaborations and Technology Commercialisation

Strategic Development and Financing

Where Global Companies Land and Grow With Us

Explore more Portfolio Stories

“Gradiant is a US-based water technology innovator specialising in advanced industrial wastewater treatment solutions. It chose Singapore as its Asia-Pacific headquarters and Global Innovation Centre to leverage the country’s well-regulated water policies and strong R&D ecosystem​. From Singapore, Gradiant drives innovation and delivers water solutions to diverse industries across the region.”

“Callio Therapeutics is a dual-headquartered biotech company based in the US and Singapore. Its proprietary multi-payload ADC platform built to deliver potent drug combinations to cancer cells, originated from cutting-edge research developed at Hummingbird Bioscience in Singapore. With its IP and early technology rooted locally, Singapore continues to be a strategic base for R&D and scientific collaboration as the company advances therapies with the potential to improve patient outcomes worldwide.”

“AlphaSense is a US-headquartered, AI-powered market intelligence platform with an Asia-Pacific innovation centre in Singapore. Since expanding into Singapore in 2023, the team has grown to over 70 full-time employees in under a year. The office plays a key role in regional product development, customer support, and cross-border data integration, serving clients across banking, consulting, and corporate sectors.”

AlphaSense

AlphaSense, headquartered in US, is the AI platform redefining market intelligence and workflow orchestration for the business and financial world, trusted by thousands of leading organizations to drive faster, more confident decisions in business and finance. Purpose-built for speed, accuracy, and enterprise-grade security, the platform combines domain specific AI with a vast content universe of over 500 million premium business documents — including equity research, earnings calls, expert interviews, filings, news, and internal proprietary content.

AlphaSense

“Since establishing our APAC hub in Singapore in 2023, AlphaSense has grown to over 70 full-time employees locally and surpassed USD 400M in global ARR. We now serve 7 of the top 10 asset managers in APAC, along with leading firms such as Chugai, Samsung, and HSBC.
SG Growth Capital has been a hugely impactful partner as we deepen our roots in Singapore and support our growing customer base in the APAC region. Their network and expertise are key as we scale to meet growing demand for AI-driven insights across Asia-Pacific.”

— Daniel Sanchez-Grant, SVP International, AlphaSense

Callio Therapeutics

Callio Therapeutics is a dual-headquartered biotech company based in Seattle and Singapore, with cutting-edge technology and programs originally developed at Hummingbird Bioscience in Singapore. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit.

Callio Therapeutics

“Singapore continues to be a strategic base for R&D and scientific collaboration as Callio Therapeutics advances therapies with the potential to improve cancer patient outcomes worldwide. SG Growth Capital has been a valuable partner in helping us build credibility and connect us with investors and the ecosystem locally and globally.”

— Piers Ingram, PhD, Chief Executive Officer and co-founder, Callio Therapeutics

Gradiant

Gradiant is a Different Kind of Water Company, delivering differentiated, proprietary solutions for advanced water and wastewater treatment. Serving mission-critical operations in essential industries such as semiconductors, pharmaceuticals, food & beverage, critical minerals, and renewables, Gradiant helps clients reduce water use, reclaim resources, and renew wastewater. Founded at MIT and headquartered in Boston, Gradiant has 1,400+ employees globally. Singapore is home to its regional headquarters and Global Innovation Centre.

Gradiant

“Singapore’s thriving innovation ecosystem, along with its world-class talent and our strong partnership with SG Growth Capital, has been instrumental in Gradiant’s ability to develop cutting-edge water technologies and become the first unicorn in the water technology sector. This collaboration has also allowed us to build strategic partnerships across the APAC region, driving our rapid growth and enabling us to create impactful solutions that address the region’s unique sustainability and regulatory challenges.”

— Govind Alagappan, President, Gradiant